Physician profile
Mark Boatright
NPI 1639152986
$1,338.97
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $16.57 · 2021: $27.21 · 2022: $789 · 2023: $25.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $201.63 | 2019-2022 | |
| Abbvie INC. | $160.35 | 2019-2023 | Venclexta |
| Janssen Scientific Affairs, LLC | $158.82 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $112.80 | 2019-2022 | |
| Beigene USA, INC. | $104.91 | 2022 | |
| Genentech USA, INC. | $92.76 | 2019-2022 | |
| Astellas Pharma US INC | $73.37 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $69.29 | 2022 | |
| Amgen INC. | $64.73 | 2019-2022 | |
| Celgene Corporation | $33.52 | 2022 | |
| Merck Sharp & Dohme LLC | $32.67 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $31.71 | 2022 | |
| Karyopharm Therapeutics INC. | $31.37 | 2022 | |
| Glaxosmithkline, LLC. | $27.11 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.87 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.46 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.33 | 2022 | |
| Incyte Corporation | $16.76 | 2022 | |
| Seagen INC. | $16.45 | 2022 | |
| Epizyme, INC. | $15.39 | 2022 | |
| Genzyme Corporation | $12.16 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $8.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Boatright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.